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Summary
Ovarian cancer is the most lethal gynaecologic cancer, in
large part because of its early dissemination and rapid
development of chemotherapy resistance. Spheroids are
clusters of tumor cells found in the peritoneal fluid of
patients that are thought to promote this dissemination.
Current models suggest that spheroids form by aggregation
of single tumor cells shed from the primary tumor. Here, we
demonstrate that spheroids can also form by budding directly
as adherent clusters from a monolayer. Formation of budded
spheroids correlated with expression of vimentin and lack of
cortical E-cadherin. We also found that compared to cells
grown in monolayers, cells grown as spheroids acquired
progressive resistance to the chemotherapy drugs Paclitaxel

Introduction
Ovarian cancer is the fifth leading cause of cancer death in
women (Jemal et al., 2010). The incidence of ovarian cancer is
lower than many other tumor types, but its mortality is higher –
over 50% – and this has not appreciably changed in the past eight
decades, although a small, recent trend towards improvement has
been seen (Jemal et al., 2010).
Ovarian cancer differs from almost all other solid tumors in
that its primary mode of dissemination is directly across the
peritoneal space, rather than through the vasculature (Shield et al.,
2009). Individual tumor cells can be shed into the peritoneum,
and a current model proposes that their aggregation into
spheroids – free-floating multicellular clusters – facilitates their
transit and implantation (Ahmed et al., 2007; Shield et al., 2009).
Spheroids have been observed in the ascites of ovarian cancer
patients and are believed to make a significant contribution to
intraperitoneal spread (Allen et al., 1987; Burleson et al., 2006;
Burleson et al., 2004).
Most of our understanding of spheroid cell biology has come
from in vitro culture of cancer cell lines. Spheroids can be
produced from many cancer cell lines under conditions that favor
cell-cell over cell-matrix adhesion, such as growth in serum-free
media, or the ‘‘hanging drop’’ method (Kelm et al., 2003; LundJohansen et al., 1989). Not all cancer cell lines form spheroids,
and the features that allow spheroid growth are not well
characterized.
A major property of cultured spheroids, including spheroids
from ovarian cancer cell lines, is resistance of spheroid cells to
cytotoxic drugs compared to the same cells grown as monolayers
(Frankel et al., 1997; Green et al., 2004; Green et al., 1999). This

and Cisplatin. This resistance could be completely reversed
by dissociating the spheroids. Our observations highlight a
previously unappreciated mode of spheroid formation that
might have implications for tumor dissemination and
chemotherapy resistance in patients, and suggest that this
resistance might be reversed by spheroid dissociation.
ß 2012. Published by The Company of Biologists Ltd. This is
an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial Share Alike
License (http://creativecommons.org/licenses/by-nc-sa/3.0).
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drug resistance is proposed to arise from one or more factors,
including creation of a physical barrier to drug penetration;
induction of genes or signalling pathways that enhance survival,
such as drug efflux pumps; and selection for a subpopulation of
drug-resistant cells, which could include cancer stem cells
(Desoize and Jardillier, 2000; Hirschhaeuser et al., 2010;
Kerbel, 1994–1995).
We observed a novel means of spheroid formation for four
ovarian cancer cell lines cultured in standard media. When the
cells were grown as adherent monolayers, spheroids arose
directly from the monolayer in dense regions and areas of
vertical cell growth. Spheroid budding correlated with the
absence of cortical E-cadherin and the presence of vimentin
filaments throughout the cells of the monolayer, suggesting that
the ability of a cell line to form spheroids was a property of the
cell line rather than a biological change only at the site of
budding. Serial passage of ovarian cancer cells between spheroid
and monolayer culture induced progressive resistance to the
chemotherapy drugs Paclitaxel and Cisplatin, and dissociating the
spheroids back into monolayers could reverse this drug
resistance. Our observations suggest that these cancer cell lines
have acquired the ability to form spheroids by budding from an
adherent monolayer, that a similar process might occur in vivo,
and that dissociating spheroids could improve ovarian cancer cell
sensitivity to chemotherapy.
Results
A novel means of spheroid formation: budding from a monolayer

When we cultured A2780 ovarian cancer cells as a monolayer
in standard culture media supplemented with 10% FBS, we
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observed formation of multilayered colonies similar to those
typically associated with loss of contact inhibition. Upon
continued culture, these colonies expanded both vertically and
horizontally. Frequently, rounded spherical clusters of cells arose
from these colonies and appeared to be attached to the monolayer
by a narrow stalk. These cell clusters eventually (within 2–3
days) detached from the monolayer, producing floating spheroids
in the media that were morphologically identical to spheroids of
this cell line formed by aggregation in commercially-available
serum-free spheroid media (Fig. 1A–C). The spheroids were of
relatively uniform size, (30 to 100 mm), similar to the size of
spheroids formed by aggregation. We called this novel type of
spheroid production ‘‘budding’’ to distinguish it from aggregation
or clonal expansion from a single cell, both of which are
established mechanisms of spheroid formation.
To assess the morphology of these budded spheroids and their
relationship to the underlying monolayer, we stained them with
the vital DNA dye DRAQ5 and imaged them using a waterimmersion lens with confocal sectioning. Imaging of living cells
was necessary because fixation caused the spheroids to break off
from the monolayer. This live-cell imaging of spheroids in
various stages of budding revealed a variety of spheroid
morphologies, including large mounds and round balls attached
to the monolayer at a single point (Fig. 1D,E).
We tested the viability of budded spheroids by several
methods. DNA staining with DRAQ5 showed occasional cells
with condensed nuclei consistent with apoptosis, at the same
frequency as in the parental monolayer. When we trypsinized
spheroids and stained with Trypan blue dye, a majority of cells
(,90%) excluded the dye. Finally, spheroids could be transferred
to a new culture dish coated with 2% Matrigel and spread as a
monolayer without obvious cell death.
We also tested growth factor requirements of budded
spheroids, to determine whether the budding process depended
on the presence of serum or added growth factors. Commercial

Fig. 1. Ovarian cancer spheroids can bud from a monolayer. A2780 cells
were grown as a monolayer in media containing serum. (A–C) Phase contrast
images of the spheroid budding process. (A) Representative spheroid budding
from the monolayer at a site of vertical expansion. (B) Representative spheroid
that had detached from the monolayer and was floating freely in the culture
media. (C) Representative spheroid plated in the presence of serum, which had
re-adhered to the culture dish and formed a new monolayer. (D,E) Fluorescence
images of a budding spheroid stained with DRAQ5 to visualize cell nuclei and
imaged while alive. The same spheroid is shown from the top, or X–Y view
(D), and the side, or Y-Z view, which was digitally reconstructed from confocal
image stacks (E). Scale bars: 30 mm.
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spheroid media is typically supplemented with a cocktail of
growth factors, some of which are proprietary, instead of serum.
We tested spheroid budding by replacing serum-containing media
with spheroid base media lacking these added growth factors.
Remarkably, A2780 spheroids could bud from a monolayer,
adhere to a new dish to form a new monolayer, and produce new
budded spheroids, in a continuous cycle for over five weeks, in
base media without any growth factors except for a 2% solution
of growth factor-reduced Matrigel used to adhere them to the
dish. This suggests that the ability to form budded spheroids does
not require supplemental serum or growth factors added to the
spheroid media.
Spheroid budding was not unique to A2780 cells. We found that
four out of six ovarian cancer cell lines produced budded spheroids:
A2780, SKOV3, HEY, and OVCA420 (Fig. 2). For most of these,
spheroids detached from the monolayer spontaneously and were
found floating in the culture media. Neither of the cell lines that
failed to form spheroids (BG1 or OVCA433) formed multilayered
colonies, suggesting that vertical growth of the monolayer might be
a prerequisite for spheroid formation.
Spheroid budding correlates with epithelial to mesenchymal
transition (EMT) markers

Spheroid budding could be due to a biological change in a subset
of cells within the monolayer, or to a global property of the cell
line. To distinguish between these possibilities, we performed a
microarray experiment to compare gene expression in A2780
cells grown as monolayers or budded spheroids. This showed no
major differences in gene expression between monolayers and
spheroids (data not shown), suggesting that altered gene
expression is unlikely to be responsible for local changes
within a subset of cells that form a budded spheroid.
We next asked whether ovarian cancer cell lines capable of
forming budded spheroids showed any properties that differed
from cell lines that failed to form budded spheroids. We focused
on proteins associated with the epithelial to mesenchymal
transition (EMT), a process that promotes cancer progression
and loss of traditional epithelial polarity (see Discussion) (Ahmed
et al., 2010; Godde et al., 2010).
We performed immunofluorescence for E-cadherin, which is
typically found at sites of cell-cell contact in epithelial monolayers,
and vimentin, which is typically expressed in mesenchymal cell
types. Of six ovarian cancer cell lines assayed, three showed a lack
of E-cadherin at cell-cell borders and the presence of vimentin
filaments throughout the cytoplasm, a typical pattern for cells that
have undergone an EMT (Fig. 2). These three cell lines (A2780,
SKOV3, and HEY) were also capable of forming budded
spheroids. A fourth cell line, OVCA420, showed lack of cortical
E-cadherin and lack of vimentin; OVCA420 cells formed budded
spheroids at a much lower frequency. In contrast, two cell lines
showed strong expression of E-cadherin at cell-cell borders and
either no vimentin (BG-1) or a low level of patchy vimentin
expression (OVCA433). Neither of these cell lines formed budded
spheroids. Thus, lack of cortical E-cadherin and the presence of
vimentin filaments correlated strongly with the ability of an
ovarian cancer cell line to form budded spheroids.
Serial passage of ovarian cancer cells between monolayer and
spheroid culture increases resistance to cytotoxic drugs

Ovarian cancer cell line spheroids formed by the liquid overlay
method were reported to show resistance to Paclitaxel but

Spheroid budding
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Fig. 2. Ability to form budded spheroids correlates with lack of cortical E-cadherin and expression of vimentin throughout the monolayer. Cell lines were
grown as monolayers and immunofluorescence for E-cadherin and vimentin performed. Top panel, E-cadherin (green) merged with DNA (blue) at 606magnification.
Middle panel, vimentin (red) merged with DNA (blue) at 606 magnification. Cell lines that failed to form budded spheroids from the monolayer showed strong
cortical E-cadherin signal and lack of vimentin (BG-1) or constant cortical E-cadherin and intermittent vimentin (OVCA433). Cell lines that formed budded spheroids
(A2780, SKOV3, HEY) showed absence of cortical E-cadherin and presence of vimentin filaments throughout the monolayer. OVCA420 cells lacked both proteins,
and formed rare budded spheroids. Bottom panel, phase contrast images of budded spheroids from these cell lines at 206 magnification. Scale bars: top and middle
panels, 20 mm; bottom panel, 50 mm.

remained sensitive to Cisplatin (Frankel et al., 1997; Kobayashi
et al., 1993). We tested the drug sensitivity of A2780 and HEY
spheroids as compared to monolayers, to determine if spheroid
formation in the absence of serum conferred drug resistance. We
were able to compare spheroids to monolayers in identical media
conditions by first seeding monolayers in media containing serum
to promote attachment to the dish, and then replacing the media
with spheroid media. Likewise, spheroids formed by budding in
serum-containing media were transferred to spheroid media prior
to drug treatments.
We tested sensitivity to Paclitaxel and Cisplatin using cells
grown in serum free media for at least 24 hours prior to drug
treatment. Cells were exposed to either drug for 24 hours, and
then trypsinized, stained with Trypan blue, and counted to
determine cell viability. As expected, cells grown in monolayers
were sensitive to both drugs, with approximately 30% of cells
viable compared to vehicle-treated samples (Fig. 3).
Interestingly, the first generation of A2780 and HEY cells
grown as spheroids were also sensitive to Paclitaxel and
Cisplatin, with approximately 30% of cells viable compared to
vehicle-treated controls (Fig. 3). This was seen both for budded
spheroids and for spheroids formed by aggregation. Thus, initial
spheroid growth did not confer drug resistance to either of these
cell lines. This was true despite significantly slower cell growth
within spheroids as compared to monolayers (the doubling time
for monolayer cells in spheroid media was ,24 hours, versus a
doubling time for spheroid cells in the same media of
,48 hours). This result implies that neither the spheroid
microenvironment nor the slower proliferation rate it conferred
was sufficient to produce resistance to these drugs.
In a separate study, we found that serial passage of the breast
cancer cell line MCF-7 as spheroids caused a wave of epigenetic
changes associated with EMT, which included acquisition of
drug resistance (Guttilla et al., 2012). These changes increased
with each successive generation of spheroid passage. To test
whether serial passage of ovarian cancer cell spheroids could

promote drug resistance, we cultured A2780 and HEY cells for
several generations of spheroid growth. Rather than trypsinizing
spheroids to create the subsequent generation, we allowed them
to dissociate spontaneously by transferring them to a culture dish
with media containing FBS, in which they spread as a monolayer.
Once the monolayer had adhered, we trypsinized the cells,
transferred them to serum-free media, and allowed them to form
spheroids by aggregation. We repeated this for three cycles, to
produce first, second and third generation monolayers and
spheroids. This method of serial passaging might approximate
an in vivo situation in which spheroids must undergo at least
partial spontaneous dissociation to implant on serosal surfaces. In
all cases, drug testing was done on samples processed in parallel
that had not previously been exposed to any drugs.
Compared to first generation spheroids, spheroids from the
second and third generation showed increasing drug resistance to
both Paclitaxel and Cisplatin. For A2780 cells treated with
Paclitaxel, cell viability increased from 37% in first generation
spheroids, to 87% in second generation spheroids, to 91% in third
generation spheroids (Fig. 3). For A2780 cells treated with
Cisplatin, viability increased from 32% in first generation
spheroids, to 84% for second generation spheroids, to 91% in
third generation spheroids.
HEY cells showed a similar progressive increase in drug
resistance. For HEY cells treated with Paclitaxel, viability
increased from 37% for first generation spheroids, to 78% for
second generation spheroids, to 90% for third generation
spheroids. For HEY cells treated with Cisplatin, viability
increased from 29% for first generation spheroids, to 82% for
second generation spheroids, to 86% for third generation
spheroids.
These data suggest that serial spheroid culture induces
progressive drug resistance with each cycle alternating between
monolayer and spheroid culture. Interestingly, whereas previous
reports of multicellular drug resistance showed an association
with spheroid compaction, with these two ovarian cancer cell
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Fig. 3. Spheroid culture induces progressive, reversible resistance to Paclitaxel and Cisplatin that is not due to an increase in spheroid size. A2780 or HEY
cells were propagated serially by alternating between monolayer and spheroid culture to produce three generations of monolayers (designated M1, 2, and 3) and three
generations of spheroids (designated S1, 2, and 3). Each generation was exposed to the indicated drugs at 7 mM in serum-free media for 24 hours, followed by Trypan
blue staining and counting of viable cells. All cells were grown in serum-free media for 24 hours before drug treatment, and no cells had been exposed to drug prior to
testing their sensitivity. (A,B) Cell number and percent viability of A2780 cells treated with vehicle (grey bars), Paclitaxel (blue bars) or Cisplatin (green bars).
(C,D) Cell number and percent viability of HEY cells treated with vehicle (grey bars), Paclitaxel (blue bars) or Cisplatin (green bars). The same data are presented as
cell number (A,C) and as percent viability (percent of control, B,D). Error bars are present for each set and show the mean and SEM of three independent repeats. The
monolayers are grouped together and spheroids are grouped together, but they were generated in the order M1RS1RM2RS2RM3RS3. (E) A change in spheroid
size or compaction was not responsible for the progressive drug resistance seen for either cell line. Representative A2780 cell first, second, and third generation
spheroids (S1, S2, S3) are shown; similar results were seen for HEY cells. Scale bars: 50 mm.

lines, subsequent generations of spheroids showed similar or
slightly reduced compaction, similar to MCF-7 cells grown
serially as spheroids (Guttilla et al., 2012; Kobayashi et al., 1993;
St. Croix et al., 1996).
Dissociation of ovarian cancer spheroids restores sensitivity to
cytotoxic drugs

Spheroid drug resistance could be due to reversible or irreversible
mechanisms. Since our method of serial spheroid passaging
alternated between spheroid and monolayer culture, we were able
to test the drug sensitivity of the intervening monolayer for each
spheroid generation. As with serial spheroid generations, this was

done in parallel samples that had not previously been treated with
any drugs. Media conditions and initial cell numbers were kept
constant.
Remarkably, dissociation of spheroids into monolayers
completely restored drug sensitivity for every generation.
A2780 monolayers treated with Paclitaxel showed 28%, 31%,
and 30% viability for first, second, and third generation
monolayers, respectively, and these monolayers treated with
Cisplatin showed 30%, 29%, and 31% viability, respectively. For
HEY cells, monolayers treated with Paclitaxel showed 29%
viability for all three generations, and monolayers treated with
Cisplatin showed 30%, 29%, and 34% viability for first, second

Spheroid budding
and third generation monolayers. Thus, the drug resistance
induced by serial passaging between monolayer and spheroid
culture was completely reversible, despite the generation of
resistance during successive spheroid generations.
Discussion
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Implications of spheroid budding from a monolayer

We describe here a novel means of spheroid formation – budding
from a monolayer of adherent cells – that required minimal
growth factor support and could continue for many cycles of
budding and dissociation. Our observation raises the possibility
that this means of spheroid formation could contribute to ovarian
cancer dissemination in patients. Spheroids could form by
budding from the primary ovarian tumor, and these budded
spheroids could dissociate and float across the peritoneum. This
could represent an additional means of spheroid formation for
cancers that can form spheroids by aggregation of single tumor
cells, and it could represent an alternate mechanism of spheroid
formation for tumor cells that lack the ability to form aggregated
spheroids.
Budding was associated with vertical growth, continued cellcell interactions, and eventual release of the budded spheroid
from the monolayer. Since cell lines capable of budding lacked
obvious cortical E-cadherin, cellular cohesion within the bud is
likely to be mediated by other cadherin- or integrin-based cellcell interactions such as through N-cadherin.
At this point, we do not know the detailed mechanism of the
budding process. Because it correlated with a lack of cortical Ecadherin and with the presence of abundant vimentin, and both of
these findings were uniform across monolayers, we believe the
ability to form budded spheroids could represent a global
property of the cancer cell line rather than a biological change
limited to distinct sites within the monolayer. If this hypothesis is
correct, it implies that the actual site of budding is likely to be
random within the monolayer.
The final step in budding is release of the spheroid from the
monolayer. This might be due to selective cell death, although we
were unable to observe an increase in dying cells near the
spheroid base. Alternatively, spheroids could detach from the
underlying monolayer through microenvironmental signals as
they enhance their attachments within the spheroid. Studies of the
biology of spheroid budding will be useful for understanding its
relationship to loss of contact inhibition and the creation of a
spheroid microenvironment.
Connection between spheroid budding and EMT

EMT is a phenomenon typically associated with epithelial cells,
for which the normal physiologic state is one of abundant cortical
E-cadherin expression and lack of vimentin. In contrast, normal
ovarian surface epithelium is mesodermally-derived and
expresses high levels of vimentin without cortical E-cadherin
(Ahmed et al., 2007; Auersperg et al., 2001). The relatively
unique ability of the ovarian surface epithelium to undergo EMTlike behavioural changes such as cell migration in response to
ovulation is thought to represent a homeostatic mechanism for
maintaining a continuous, intact epithelial layer (Ahmed et al.,
2010).
During tumorigenesis, ovarian cancer cells can adopt an
aberrant mullerian differentiation pattern, in which they gain
expression of cortical E-cadherin and lose expression of vimentin
(Ahmed et al., 2010; Auersperg et al., 2001; Hudson et al., 2008).
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At later stages of the disease that are associated with greater
dissemination, ovarian cancers lose this pattern and again become
cortical E-cadherin negative and vimentin positive (Ahmed et al.,
2010; Auersperg et al., 2001; Hudson et al., 2008). Ovarian
cancers may thus show a high degree of phenotypic plasticity, as
described for normal ovarian surface epithelium, and the concept
of EMT in this tumor type may be more complex than in others
(Ahmed et al., 2007). We hypothesize that a lack of cortical Ecadherin and the presence of vimentin alone is insufficient for
spheroid budding, because immortalized ovarian surface
epithelium (IOSE) cells with this pattern did not form budded
spheroids (data not shown). However, this EMT-like pattern in
malignant ovarian cancer cells correlated with the ability to form
budded spheroids, suggesting it might contribute to the budding
process or be a marker for the ability to form budded spheroids.
Reversible drug resistance in ovarian cancer spheroids

Despite their slower growth, spheroids formed by budding or
aggregation initially showed sensitivity to cytotoxic drugs that
was equivalent to monolayers. This was followed by progressive
acquisition of drug resistance during several cycles of spheroid
passaging. This acquired drug resistance was not due to prior
drug exposure, because each generation of spheroids had not
been exposed to any drugs prior to testing their drug sensitivity.
Therefore, it must have been induced by the sequential culture
protocol.
The mechanism of progressive drug resistance upon serial
spheroid passaging remains unexplained. Breast cancer cells
cultured serially as spheroids underwent an EMT with reduced
expression of E-cadherin and gain of vimentin expression
(Guttilla et al., 2012). However, the ovarian cancer cells we
tested express abundant vimentin and minimal E-cadherin at
baseline, consistent with these EMT-associated properties prior
to the acquisition of drug resistance. Thus, a traditional EMT
cannot fully account for the acquired drug resistance. It is
possible that these cancer cell lines exist in a state of partial EMT
that is enhanced upon further cycles of spheroid culture.
The resistance of A2780 cells to Paclitaxel upon multicellular
spheroid growth was demonstrated by Kerbel’s group 15 years
ago (Frankel et al., 1997). Interestingly, that study also tested
Cisplatin treatment and found that resistance upon spheroid
culture did not extend to this agent (Frankel et al., 1997). Our
finding of Cisplatin resistance could be due to the method of
spheroid growth (serum free growth with added growth factors
instead of liquid overlay in the presence of serum). Further, our
study did not demonstrate drug resistance with the first spheroid
generation, while Frankel et al. observed resistance in de novo
spheroids. Finally, our finding of resistance to two drugs with
distinct mechanisms of action (microtubule stabilization versus
DNA crosslinking) suggests the resistance is unlikely to be
specific to the drug mechanism, but might arise from alterations
in drug transport or the cell death machinery.
What additional differences between first, second, and third
generation spheroids could confer drug resistance? Genetic
changes are unlikely, because these would not be rapidly
acquired, reversible, or reproducible in two different cell lines.
We also do not think the reduced growth rate of spheroids is
responsible, because this reduced growth rate was seen in the first
generation of spheroids, which were not drug resistant. Spheroid
size and compaction also did not change appreciably from one
spheroid generation to the next (Fig. 3E), arguing against a
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purely physical change being responsible for progressive drug
resistance. A further experiment to test whether spheroid size
could account for differing drug sensitivity by size-selecting
spheroids through a 40 mm filter did not show greater drug
resistance in larger spheroids (data not shown).
Epigenetic changes are a possible explanation for increasing
drug resistance upon serial spheroid culture, but these would have
to be rapidly reversible or be counteracted by monolayer growth.
Altered signalling pathways that block cell death might be
engaged upon loss of integrin contacts with the extracellular
matrix and restored upon reestablishment of these contacts.
However, this would not explain the progressive increase in drug
resistance from one spheroid generation to the next. The
explanation for the progressive drug resistance might therefore
include a combination of epigenetic and signalling changes,
possibly with some EMT characteristics. Studies to test the
mechanism of drug resistance are ongoing.
Regardless of the drug resistance mechanism, our study
demonstrates that drug sensitivity can be restored to ovarian
cancer cells, even after multiple rounds of spheroid formation, by
simply dissociating the cells. This is true for two independent
ovarian cancer cell lines and for two drugs with different
mechanisms of action. This is consistent with findings by other
groups that show dissociation of spheroids from other cancer
types reverses drug resistance, and suggests that strategies to
dissociate spheroids in vivo could be effective in increasing the
efficacy of cytotoxic drugs (Frankel et al., 1997; Green et al.,
2004; Green et al., 2002; Kobayashi et al., 1993). Ovarian cancer
spheroids might be especially amenable to dissociation since they
are confined to the peritoneal space.
Strategies to dissociate ovarian cancer spheroids in vivo could
include calcium chelators that disrupt cell-cell contacts.
Remarkably, intraperitoneal chelators such as EGTA have been
well tolerated in animals at reasonably high doses (Llobet et al.,
1991; Llobet et al., 1990). To date, we are not aware of the use of
antiadhesive agents as a means to chemosensitize tumors in
human trials, although anti-N-cadherin antibodies were given as a
single agent (without concomitant cytotoxic drugs) and were well
tolerated (Perotti et al., 2009). For ovarian tumors, many of
which do not express E-cadherin, these therapies would need to
target other cadherins and possibly integrin family members.
The intraperitoneal dissemination of ovarian cancer makes this
tumor a particularly attractive candidate for testing anti-adhesive
approaches.
Materials and Methods
Cell lines
A2780 cells were purchased from European Collection of Cell Cultures (ECACC,
Salisbury, Wiltshire, UK) and grown in RPMI 1640 with 2mM Glutamine and 10%
fetal bovine serum (FBS, not heat inactivated). OVC433 and OVCA420 cells (gift
from Dr. Laurie Hudson, University of New Mexico Health Sciences Center,
Albuquerque, NM) were grown in MEME plus 0.5% penicillin/streptomycin, 1%
Glutamine, 1% Sodium Pyruvate, and 10% FBS. BG1 cells (gift from Matthew
Burow, Tulane University School of Medicine, New Orleans, LA) were grown in
DMEM plus 10% FBS. SKOV3 cells (gift of Zou Changpeng, University of CT
Health Center, Farmington, CT) were grown in DMEM-F12 plus 10% FBS. HEY cells
(gift from Dr. Robert Bast, MD Anderson Cancer Center, Houston, Texas) were grown
in DMEM-F12 plus 10% FBS. All cells were kept at 37˚C in a 5% CO2 incubator.

Spheroid culture
Spheroid formation
Aggregated spheroids were formed by culturing cells in serum-free media on low
adhesion tissue culture plates in one of two commercial media preparations:
Mammocult Mammosphere media supplemented with a proprietary cocktail plus
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heparin and hydrocortisone (Stem Cell Technologies, Vancouver, BC, Canada), or
Mammary Epithelium Spheroid Media supplemented with hydrocortisone, bovine
pituitary extract, epidermal growth factor (rhEGF), insulin, and antibiotics (Lonza
Walkersville Inc., Walkersville, MD).
Budding spheroids were formed by culturing cells in their regular growth media
on adherent plates and allowing spheroids to form spontaneously. HEY cells were
cultured as a monolayer in their regular growth media followed by growth in
Mammocult media (Lonza) for budding.
Spheroid dissociation
We tested several methods of dissociating spheroids: trypsinization, calcium
chelation with EGTA, mechanical trituration, and allowing spheroids to dissociate
spontaneously by plating them in serum-containing media or plating them in
spheroid media on plates pre-coated with 2% Matrigel (growth factor reduced,
phenol red free; BD Biosciences, Bedford, MA). Spontaneous dissociation was
associated with the least cell death, and resulting monolayers showed equal ability
as standard monolayers to produce new budding spheroids.

Immunofluorescence
Cells were grown on glass coverslips to near-confluence. E-cadherin was detected
after fixing cells in 4% formaldehyde, using a rat anti-E-cadherin antibody from
Invitrogen (Camarillo, CA) (dilution 1:80) and Oregon-green goat anti-rat
secondary antibody from Molecular Probes (Eugene, OR). Vimentin was
detected after fixing cells in ice-cold methanol for 5 minutes, using mouse antiVimentin antibody Ab-2 (Clone V9) from Thermo Scientific (Fremont, CA)
(dilution 1:100) and Alexa-568 anti-mouse secondary antibody (Molecular
Probes). DNA was stained with Hoechst stain at 10 mg/ml. Coverslips were
mounted using 0.5% p-phenylenediamine in 20 mM Tris 8.8 and 90% glycerol.

Microscopy
Budded spheroids could only be imaged live, as fixation caused these spheroids to
detach from the monolayer. Phase contrast imaging was done using a 46 or 206
objective on a Nikon inverted microscope (TE2000-U, Nikon Instruments,
Melville, NY) equipped with an ORCA AG CCD camera (Hamamatsu
Photonics, Bridgewater, NJ) and controlled by MetaMorph software (Molecular
Devices Corp, Sunnyvale, CA).
Fluorescence imaging of budded spheroids was done on cells grown on glass
coverslips. Cell nuclei were stained with DRAQ5 (Biostatus, Leicestershire, UK)
at 5 mM for 20 minutes prior to imaging. Cells were imaged live using a 406 1.2
NA c-apochromat water immersion lens on a Carl Zeiss, Inc. LSM510 laser
scanning confocal microscope equipped with a MetaDetector spectral detector
(Thornwood, NY). Optical sections were collected at 0.5 mm steps.
Immunofluorescence was imaged using a 606 objective on a Nikon TE2000-U
microscope with a spinning disk confocal head (Perkin Elmer; Wellesley, MA)
controlled by MetaMorph software.

Drug treatments
Paclitaxel (Taxol, Sigma Aldrich, St Louis, MO) was reconstituted as a 10 mM stock
solution in DMSO. Cis-Diammineplatinum (II) dichloride (Cisplatin, Sigma Aldrich)
was reconstituted as a 5 mM stock solution in phosphate buffered saline (PBS).
Spheroids and monolayers were plated at 16103 cells/well in 24 well low
adhesion plates in regular growth media containing serum (monolayers) or Lonza
spheroid media (spheroids). Monolayer 2 was produced from the spontaneous
dissociation of Spheroid 1 onto a culture dish in media containing FBS; Spheroid 2
was produced from the natural budding of Monolayer 2 or the aggregation of
Monolayer 2 cells; Monolayer 3 was produced from the natural dissociation of
Spheroid 2; and Spheroid 3 was produced from the natural budding or aggregation
of Monolayer 3.
To eliminate effects of serum on drug bioavailability and cell proliferation,
media for all spheroids and monolayers was exchanged for Lonza spheroid media
after 24 hours of growth, and cells were cultured for an additional 24 hours in this
media before drug treatment. Monolayers or spheroids were treated with Paclitaxel
or Cisplatin at a final concentration of 7 mM for 24 hours. These treatments were
done on samples processed in parallel, so no drug treatment was done on cells that
had previously been exposed to any drug. Viability was determined by trypsinizing
cells, staining with Trypan blue, counting, and calculating total numbers of viable
and dead cells, in triplicate, in at least two independent experiments for each
condition. Drug sensitivity for budded spheroids and spheroids formed by
aggregation in serum free media were found to be the same; thus, most drug
experiments were done using aggregated spheroids since we could generate greater
numbers of these more quickly. Graphs of drug resistance were made using Prism
(GraphPad Software, La Jolla, CA).
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